Frank Sirotnak

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

Owen A. O’Connor, Steven M. Horwitz, Paul A. Hamlin et al. · Journal of Clinical Oncology · 2009 · 181 citations

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

David B. Solit, Yuhong She, Jose Lobo et al. · Clinical Cancer Research · 2005 · 134 citations · Full text

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

Owen A. O’Connor, Paul A. Hamlin, Carol S. Portlock et al. · British Journal of Haematology · 2007 · 86 citations

Refractory Aggressive Tcl, T‐cell Lymphoma, Immunology +21

Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro

Hong Lin, Yuhong She, Barrie R. Cassileth et al. · International Immunopharmacology · 2003 · 78 citations

Bone Marrow Failure, Medicine, Hematology +6

The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma

Lorraine E. Toner, Radovan Vrḫovac, Emily A. Smith et al. · Clinical Cancer Research · 2006 · 69 citations · Full text